Novartis AG to Discuss Ofatumumab (OMB157) ECTRIMS Data Investor Call Transcript
Good morning, and good afternoon, and welcome to the Novartis Investor Call. (Operator Instructions) And the conference is being recorded. (Operator Instructions) With that, I would like to hand over to Samir Shah, Global Head, Investor Relations. Please go ahead, sir.
Thank you very much, and good morning, and good afternoon, everybody. And thank you for taking the time to join us today as we go through the ECTRIMS data, which was presented last Friday. With myself in the room, we have Marie-France Tschudin. She is the -- as you know, she is the Head of Pharmaceuticals Division within Novartis. We also have Danny Bar-Zohar, who is the Global Development and Analytics Head; and Paul Spittle, who's the Global Commercial Head for Pharmaceuticals Division.
Before we actually start, just a couple of points to mention. The slides for this investor call are available on our website. And I'll also like to read you the safe harbor statement. The information presented today contains forward-looking statements that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
